Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review.

Hans Van RemoortelHans ScheersBert AvauJørgen GeorgsenSusan NahirniakNadine ShehataSimon J StanworthEmmy De BuckVeerle CompernollePhilippe Vandekerckhove

Published in: PharmacoEconomics (2023)

Cost-effectiveness of TPO mimetics in adult patients with thrombocytopenia ranged from a dominant strategy to a significant incremental cost per QALY/health outcome or a strategy that is clinically inferior and has increased costs. Future validation and tackling the uncertainty of these models with country-specific cost data and up-to-date efficacy and safety data are needed to increase the generalizability.

Keyphrases

electronic health record
healthcare
public health
health information
machine learning
social media
risk assessment
data analysis
health promotion
artificial intelligence